1. Home
  2. VYNE vs AAME Comparison

VYNE vs AAME Comparison

Compare VYNE & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYNE
  • AAME
  • Stock Information
  • Founded
  • VYNE 2003
  • AAME 1968
  • Country
  • VYNE United States
  • AAME United States
  • Employees
  • VYNE N/A
  • AAME N/A
  • Industry
  • VYNE Biotechnology: Pharmaceutical Preparations
  • AAME Life Insurance
  • Sector
  • VYNE Health Care
  • AAME Finance
  • Exchange
  • VYNE Nasdaq
  • AAME Nasdaq
  • Market Cap
  • VYNE 41.9M
  • AAME 34.5M
  • IPO Year
  • VYNE 2018
  • AAME N/A
  • Fundamental
  • Price
  • VYNE $2.49
  • AAME $1.48
  • Analyst Decision
  • VYNE Strong Buy
  • AAME
  • Analyst Count
  • VYNE 2
  • AAME 0
  • Target Price
  • VYNE $6.88
  • AAME N/A
  • AVG Volume (30 Days)
  • VYNE 70.8K
  • AAME 6.2K
  • Earning Date
  • VYNE 11-07-2024
  • AAME 11-12-2024
  • Dividend Yield
  • VYNE N/A
  • AAME 2.70%
  • EPS Growth
  • VYNE N/A
  • AAME N/A
  • EPS
  • VYNE N/A
  • AAME N/A
  • Revenue
  • VYNE $493,000.00
  • AAME $185,929,000.00
  • Revenue This Year
  • VYNE $28.30
  • AAME N/A
  • Revenue Next Year
  • VYNE N/A
  • AAME N/A
  • P/E Ratio
  • VYNE N/A
  • AAME N/A
  • Revenue Growth
  • VYNE 39.27
  • AAME 0.35
  • 52 Week Low
  • VYNE $1.57
  • AAME $1.26
  • 52 Week High
  • VYNE $3.43
  • AAME $3.00
  • Technical
  • Relative Strength Index (RSI)
  • VYNE 40.82
  • AAME 44.06
  • Support Level
  • VYNE $2.34
  • AAME $1.48
  • Resistance Level
  • VYNE $2.69
  • AAME $1.55
  • Average True Range (ATR)
  • VYNE 0.19
  • AAME 0.05
  • MACD
  • VYNE -0.04
  • AAME 0.00
  • Stochastic Oscillator
  • VYNE 13.79
  • AAME 30.00

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts. It also provides tailored business automobile insurance coverage, on a multi-year contract basis, to state governments and local municipalities, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance. It earns revenue from the collection of premiums and investment income.

Share on Social Networks: